Mer­ck KGaA en­trusts se­cre­tive start­up with a mid-stage can­cer drug tar­get­ing mas­ter sig­nal­ing path­way

A se­cre­tive French biotech has im­port­ed a drug from Ger­many’s Mer­ck KGaA that will leapfrog the small com­pa­ny right in­to mid-stage test­ing against can­cer.

Di­ac­cu­rate has in-li­censed Mer­ck KGaA’s M2698 — now dubbed DI­ACC3010 — a “PAM” in­hibitor that is geared up for Phase II stud­ies in both sol­id tu­mors and hema­to­log­i­cal ma­lig­nan­cies, the French biotech said ear­ly Wednes­day morn­ing.

Fi­nan­cial terms of the deal were not dis­closed, but Mer­ck KGaA said in a re­lease it chose to work with Di­ac­cu­rate af­ter a “high­ly com­pet­i­tive se­lec­tion process” that re­ward­ed the biotech’s “strong sci­en­tif­ic back­ground.” Mer­ck KGaA will be­come a share­hold­er in Di­ac­cu­rate as part of the part­ner­ship, the com­pa­nies said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER